Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "global-operations"

43 News Found

AstraZeneca to set up API facility in Ireland at an investment of US $ 360 million
Supply Chain | September 21, 2021

AstraZeneca to set up API facility in Ireland at an investment of US $ 360 million

The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes

Alkem launches Ibuprofen and Famotidine tablets in US
News | August 07, 2021

Alkem launches Ibuprofen and Famotidine tablets in US

Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg

Alkem launches Perampil tablets at affordable prices
News | June 11, 2021

Alkem launches Perampil tablets at affordable prices

The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access

Upcoming E-conference
June 19, 2026 The Future of Clinical Research in India: Can India Become a Global Trial Hub?
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Alithea Genomics, Revvity partner to expand global access to Transcriptomics for drug discovery

T-CURX gets Swissmedic nod for first human trial of non-viral CAR-T therapy

Ramkrishna CARE Hospitals’s dedicated cancer institute to open in August 2026

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
From bench to work flow, we are an integrated solution provider: K.O. Satish, Associate Vice President, Spinco Biotech
From bench to work flow, we are an integrated solution provider: K.O. Satish, Associate Vice President, Spinco Biotech

Packaging